Literature DB >> 8174068

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia.

G J Swansbury1, S D Lawler, G Alimena, D Arthur, R Berger, H Van den Berghe, C D Bloomfield, A de la Chappelle, G Dewald, O M Garson.   

Abstract

Patients with acute myeloid leukemia (AML, equivalent to acute non-lymphoblastic leukemia [ANLL]) who were studied at the Fourth and Sixth International Workshops on Chromosomes in Leukemia and who have long survival have been re-assessed to identify factors which may be associated with good prognosis in AML. In a long-term survivor (LTS) group, there were more cases than expected in each age decade below 50, more cases than expected with FAB type M3, and fewer cases than expected of secondary leukemia. Of the distribution of chromosome abnormalities, t(15;17), t(8;21), and inv/del(16) were over-represented, and -5, -7, and rearrangements of 11q were under-represented. Multivariate analysis of all patients showed that age group, cytogenetic classification, FAB type, and sex all had independent, significant effects on survival. A new observation from a very small subgroup of patients was that deletion of 7q without concurrent abnormality of chromosome 5 appeared to be associated with a good prognosis.

Entities:  

Mesh:

Year:  1994        PMID: 8174068     DOI: 10.1016/0165-4608(94)90174-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

Review 1.  Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia.

Authors:  S Bolam; T Hamblin
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

2.  Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Authors:  Andres Jerez; Yuka Sugimoto; Hideki Makishima; Amit Verma; Anna M Jankowska; Bartlomiej Przychodzen; Valeria Visconte; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Austin G Kulasekararaj; Andrea Pellagatti; Kathy McGraw; Hideki Muramatsu; Alison R Moliterno; Mikkael A Sekeres; Michael A McDevitt; Seiji Kojima; Alan List; Jacqueline Boultwood; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

3.  Improved outcome of acute myeloid leukaemia in Down's syndrome.

Authors:  J L Craze; G Harrison; K Wheatley; I M Hann; J M Chessells
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

Review 4.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 5.  Is it important to decipher the heterogeneity of "normal karyotype AML"?

Authors:  Stephen D Nimer
Journal:  Best Pract Res Clin Haematol       Date:  2008-03       Impact factor: 3.020

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.